APELA: A Drug Target / Disease Biomarker (G100506013)

Target Name: APELA

NCBI ID: G100506013

APELA

APELA: A Drug Target / Disease Biomarker

APELA is a protein that is expressed in the brain and is known to play a role in the development and progression of several neurological disorders, including Alzheimer's disease. It is also a potential drug target for several diseases, including Alzheimer's disease.

The protein APELA is composed of 1,200 amino acids and has a molecular weight of 19.9 kDa. It is located in the brain and is involved in the formation and maintenance of the blood-brain barrier, which is a barrier that separates the brain from the surrounding blood vessels.

One of the functions of APELA is to regulate the movement of neurons in the brain. It is known to play a role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. This is important for the development and progression of several neurological disorders, including Alzheimer's disease.

APELA is also involved in the regulation of neurotransmitter release from neurons. It is known to play a role in the regulation of the release of dopamine, a neurotransmitter that is involved in mood, emotion, and motivation.

In addition to its role in the regulation of synaptic plasticity and neurotransmitter release, APELA is also involved in the regulation of inflammation in the brain. It is known to play a role in the regulation of the immune response in the brain and is involved in the production of several factors that help to protect the brain from inflammation.

As a potential drug target, APELA is being studied for its potential to treat several neurological disorders, including Alzheimer's disease. Studies have shown that APELA is involved in the development and progression of Alzheimer's disease and that it may be a useful target for the development of new treatments for this disease.

One way that researchers are studying APELA as a potential drug target is through the use of techniques such as RNA interference and live cell imaging. These techniques allow researchers to manipulate the expression of APELA and to study its effects on the behavior and health of neurons in the brain.

Another way that researchers are studying APELA is through the use of animal models. Researchers have used mice to study the effects of APELA on the development and progression of Alzheimer's disease. They have found that APELA is involved in the development of several neurological symptoms that are similar to those observed in Alzheimer's disease.

In addition to its potential as a drug target, APELA is also being studied as a biomarker for the development and progression of Alzheimer's disease. Studies have shown that the expression of APELA is significantly increased in the brains of individuals with Alzheimer's disease compared to those without the disease. This suggests that APELA may be a useful biomarker for the diagnosis and prognosis of Alzheimer's disease.

Overall, APELA is a protein that is involved in several important functions in the brain, including the regulation of synaptic plasticity, neurotransmitter release, and inflammation. Its potential as a drug target and biomarker for Alzheimer's disease makes it an important area of research for scientists and doctors. Further studies are needed to fully understand the role of APELA in the development and progression of Alzheimer's disease.

Protein Name: Apelin Receptor Early Endogenous Ligand

Functions: Endogenous ligand for the apelin receptor (APLNR) (PubMed:25639753, PubMed:28137936). Hormone required for mesendodermal differentiation, blood vessels formation and heart morphogenesis during early development and for adult cardiovascular homeostasis (PubMed:25639753, PubMed:28137936). Drives internalization of APLNR. Acts as a motogen by promoting mesendodermal cell migration during gastrulation by binding and activating APLNR. Acts as an early embryonic regulator of cellular movement with a role in migration and development of cardiac progenitor cells. May act as a chemoattractant for the activation of angioblast migration toward the embryonic midline, i.e. the position of the future vessel formation, during vasculogenesis. Positively regulates sinus venosus (SV)-derived endothelial cells migration into the developing heart to promote coronary blood vessel sprouting. Plays a role in placental vascular development; promotes placental trophoblast invasion and spiral artery remodeling in the uterus. Involved in the regulation of maternal cardiovascular homeostasis to prevent gestational hypertension and for potent cardioprotective functions during heart failure. Mediates myocardial contractility in an ERK1/2-dependent manner (By similarity)

The "APELA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APELA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets